Reslizumab has a volume of distribution of approximately 5 L, clearance of approximately 7 mL/hour, and a half-life of about 24 days. Reslizumab is degraded by enzymatic proteolysis into small peptides and amino acids, as are other monoclonal antibodies.
Reslizumab's pharmacokinetic profile includes a volume of distribution of about 5 L, clearance rate of approximately 7 mL/hour, and half-life of roughly 24 days. Reslizumab is metabolized through enzymatic proteolysis into smaller peptides and amino acids, similar to other monoclonal antibodies used in therapeutic applications.